Neonatal Transcatheter Cardiac Interventions at Sohag University Hospital

NCT ID: NCT06126484

Last Updated: 2023-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is performed to assess the safety, efficacy and outcome of transcatheter cardiac interventions in neonates with critical congenital heart disease at Sohag University Hospital

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study includes neonates with critical congenital heart diseases that require early interventions Patients with untreated sepsis and coagulopathy are excluded.

Methods:

A) Clinical data: age, body weight and oxygen saturation B) Echocardiographic data: cardiac anatomical diagnosis. C) Catheterization data: vascular access, description of the defects, type of the device used, fluoroscopy time, radiation time, related complications and added interventions in the same setting.

D) Procedural details:

* All procedures will be performed under general anesthesia. procedures will be performed are;

1. Balloon atrial septostomy.
2. PDA stent implantation.
3. Pulmonary valvuloplasty.
4. Aortic valvuloplasty.
5. Balloon angioplasty of coarctation.
6. PDA device closure for preterm neonates.

E) Post-procedure details:
* All the patients will be transferred to NICU.
* Prophylactic antibiotic therapy will be given to all patients.
* In patients with PDA stent; heparin infusion will be maintained for at least for 24-48 hours then acetylsalicylic acid: Dose; 5mg/kg/day will be added when oral feeding could be established until undergoing second-stage palliation or repair.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transcatheter Neonatal Cardiac Interventions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neonates with congenital heart disease

Neonates with critical congenital heart diseases that require early catheter intervention

Group Type OTHER

transcatheter cardiac intervention

Intervention Type PROCEDURE

Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcatheter cardiac intervention

Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Neonates with critical congenital heart diseases that require early intervention

Exclusion Criteria

* Untreated sepsis and coagulopathy.
Minimum Eligible Age

1 Hour

Maximum Eligible Age

30 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Somia Sabry Mahmoud

Assistant lecturer of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Somaia S Mahmoud, Master

Role: PRINCIPAL_INVESTIGATOR

Faculty of Medicine, Sohag University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Somaia S Mahmoud, Master

Role: CONTACT

201019052097

Safaa H Ali, professor

Role: CONTACT

201064818849

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Somaia S Mahmoud, Master

Role: primary

201019052097

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-23-10-04MD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.